United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - vinblastine sulfate (unii: n00w22yo2b) (vinblastine - unii:5v9klz54cy) - vinblastine sulfate 1 mg in 1 ml - vinblastine sulfate injection is indicated in the palliative treatment of the following: i. frequently responsive malignancies - generalized hodgkin’s disease (stages iii and iv, ann arbor modification of rye staging system) - lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) - histiocytic lymphoma - mycosis fungoides (advanced stages) - advanced carcinoma of the testis - kaposi’s sarcoma - letterer-siwe disease (histiocytosis x) ii. less frequently responsive malignancies - choriocarcinoma resistant to other chemotherapeutic agents - carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents.  for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected.  therefore, although vinblastine

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vinblastine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - used in the treatment of hodgkins' disease (stages iii and iv) in combination therapy (with adriamycin, bleomycin and dacarbazine as abvd) and in the treatment of advanced testicular carcinoma (with cisplatin and bleomycin). in the palliative treatment of lymphocytic lymphoma, histiocytic lymphoma, kaposi's sarcoma and histiocytosis x. advanced stages of mycosis fungoides. may be used in the treatment of choriocarcinoma resistant to other chemotherapeutic agents; carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - vinblastine sulfate - solution for injection/infusion - 1 milligram(s)/millilitre - vinca alkaloids and analogues; vinblastine

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - vinblastine sulfate - solution for inj/inf - 1 mg/ml - vinca alkaloids and analogues

Canada - English - Health Canada

sandoz canada incorporated - vinblastine sulfate - solution - 1mg - vinblastine sulfate 1mg - antineoplastic agents

Canada - English - Health Canada

pfizer canada ulc - vinblastine sulfate - solution - 1mg - vinblastine sulfate 1mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - vinblastine sulfate - solution - 1mg - vinblastine sulfate 1mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - vinblastine sulfate 10mg - powder for injection - 10 mg - active: vinblastine sulfate 10mg excipient: benzyl alcohol sodium chloride water for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - vinblastine sulfate - solution for injection - 1mg/1ml

Israel - English - Ministry of Health

abic marketing ltd, israel - vinblastine sulfate - solution for injection - vinblastine sulfate 1 mg / 1 ml - vinblastine - vinblastine - vinblastine has proved effective in the treatment of the following neoplasms, either alone or in conjunction with other oncolytic drugs:frequently responsive malignancies :• generalized hodgkin's disease (stages iii and iv, ann arbor modification of rye staging system)• non-hodgkin's lymphoma: - reticulum-cell sarcoma - lymphosarcoma• mycosis fungoides.• neuroblastoma.• histiocytosis x.less frequently responsive malignancies :• choriocarcinoma resistant to other chemotherapeutic agents.• embryonal carcinoma of the testis.• carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.